# Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

> **NCT00621322** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 180 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** GSK Biologicals' AS01B adjuvant
- **BIOLOGICAL:** GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1
- **BIOLOGICAL:** GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2
- **BIOLOGICAL:** GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3
- **BIOLOGICAL:** GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1
- **BIOLOGICAL:** GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2

## Key facts

- **NCT ID:** NCT00621322
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-03
- **Primary completion:** 2009-04-03
- **Final completion:** 2009-04-03
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2018-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621322, "Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00621322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*